retatrutide clinical trials brazil Retatrutide: A Promising Option for Non-Diabetic Weight Loss in Eli Lilly's Phase 3 data

This is not a drug where a lower dose gives you most of the benefit

Log your doses

After approval, Eli Lilly needs to manufacture enough supply, negotiate insurance coverage, set up distribution, and train healthcare providers on the new drug

In a phase 3 clinical trial, the medication retatrutide helped control blood sugar levels in participants with type 2 diabetes and led to an average of up to 36.6 pounds of weight loss, according to drugmaker Eli Lilly

In a landmark Phase 2 trial published in the New England Journal of Medicine, participants receiving the 12 mg dose experienced mean weight loss of 24.2% at 48 weeks, significantly exceeding results from earlier GLP-1 or dual-agonist therapies

10.1038/s41598-025-89408-z 50 HeL.WangJ.PingF.YangN.HuangJ.LiY.et al (2022)